<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03233126</url>
  </required_header>
  <id_info>
    <org_study_id>KRN23-003</org_study_id>
    <nct_id>NCT03233126</nct_id>
  </id_info>
  <brief_title>A Study of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia</brief_title>
  <official_title>A Phase 3 Open-Label Trial to Assess the Efficacy and Safety of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Kirin Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Hakko Kirin Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the efficacy and safety of KRN23 administered
      subcutaneously once every 2 weeks in children with X-linked hypophosphatemic
      rickets/osteomalacia(XLH)
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 6, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects for each adverse events</measure>
    <time_frame>up to week 88</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects for each adverse events</measure>
    <time_frame>up to week 88</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect to pulse rate</measure>
    <time_frame>up to week 88</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect to respiratory rate</measure>
    <time_frame>up to week 88</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect to blood pressure</measure>
    <time_frame>up to week 88</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect to 12-Lead Electrocardiogram</measure>
    <time_frame>up to week 88</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect to Renal Ultrasound</measure>
    <time_frame>up to week 88</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect to Echocardiogram</measure>
    <time_frame>up to week 88</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum phosphorus concentration at each test time point</measure>
    <time_frame>up to week 88</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1,25(OH)2D at each test time point</measure>
    <time_frame>up to week 88</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alkaline phosphatase at each test time point</measure>
    <time_frame>up to week 88</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine phosphorus at each test time point</measure>
    <time_frame>up to week 88</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tubular reabsorption of phosphate at each test time point</measure>
    <time_frame>up to week 88</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TmP/GFR at each test time point</measure>
    <time_frame>up to week 88</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in serum phosphorus</measure>
    <time_frame>up to week 88</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 1,25(OH)2D</measure>
    <time_frame>up to week 88</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in alkaline phosphatase</measure>
    <time_frame>up to week 88</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in urine phosphorus</measure>
    <time_frame>up to week 88</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in tubular reabsorption of phosphate</measure>
    <time_frame>up to week 88</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in TmP/GFR</measure>
    <time_frame>up to week 88</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Radiographic Global Impression of Change(RGI-C) global score</measure>
    <time_frame>up to week 88</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on Rickets Severity Score (RSS) total score</measure>
    <time_frame>up to week 88</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Six Minute Walk Test</measure>
    <time_frame>up to week 88</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in height-for-age z-scores from baseline</measure>
    <time_frame>up to week 88</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profiles of maximum concentration (Cmax)</measure>
    <time_frame>up to week 88</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profiles of half-life (t1/2)</measure>
    <time_frame>up to week 88</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profiles of area under the curve (AUC)</measure>
    <time_frame>up to week 88</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>X-linked Hypophosphatemic Rickets/Osteomalacia</condition>
  <arm_group>
    <arm_group_label>KRN23</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KRN23</intervention_name>
    <description>Subjects will receive subcutaneous injections of KRN23 every 2 weeks from Week 0 through Week 86</description>
    <arm_group_label>KRN23</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Personally submitted voluntary written informed consent by a legally authorized
             representative.If appropriate, written or verbal assent to participate in the study
             should be obtained from patients.

          2. Aged ≥ 1 and ≤12 years

          3. Patients who have open growth plate

          4. Willing to perform a self-administration of KRN23 and available to perform a
             self-administration

          5. Diagnosis of XLH, and meeting any of the followings;

               1. phosphate-regulating gene with homologies to endopeptidases on the X
                  chromosome(PHEX) mutation in either the patient or in a directly related family
                  member with appropriate X-linked inheritance

               2. Serum intact FGF23 level at screening ≥ 30 pg/mL

          6. Finding evidence of rickets or clinical symptoms

          7. Meeting all of following criteria for laboratory test related to XLH;

               1. Serum P: &lt; 3.0 mg/dL

               2. Serum Cr: Within the age-adjusted normal limits

               3. Serum 25(OH)D: ≥ 16 ng/mL

          8. For female patients who have reached menarche with child bearing potential; a negative
             urine pregnancy test at screening

          9. For female patients with child baring potential, or male patients with reproductive
             capacity; willingness to use an acceptable method of contraception while participating
             in the study

         10. Willingness to provide access to prior medical records to determine eligibility
             including data on imaging tests, blood chemistry, diagnosis, medication, and surgical
             history

         11. Willingness and ability to cooperatively complete all study procedures, adhere to the
             visit schedule and follow the investigator's instructions, as considered by the
             investigator or subinvestigator

        Exclusion Criteria:

          1. Height percentile &gt; 50% based on age-adjusted Japanese norms at screening

          2. Use of aluminum hydroxide antacids, systemic corticosteroids, acetazolamide, and
             thiazides within 7 days prior to screening

          3. Current or prior use of leuprorelin, triptorelin, goserelin, or other drugs known to
             delay puberty

          4. Use of growth hormone therapy within 12 months before screening

          5. Use of medication to suppress parathyroid hormone within 60 days prior to screening

          6. Serum calcium levels outside the age-adjusted normal limits

          7. Intact parathyroid hormone(iPTH) levels ≥ 163 pg/mL

          8. Presence of nephrocalcinosis on renal ultrasound grade 4 based on the following scale:

             &quot;0&quot; = Normal &quot;1&quot; = Faint hyperechogenic rim around the medullary pyramids &quot;2&quot; = More
             intense echogenic rim with echoes faintly filling the entire pyramid &quot;3&quot; = Uniformly
             intense echoes throughout the pyramid &quot;4&quot; = Stone formation: solitary focus of echoes
             at the tip of the pyramid

          9. Planned or recommended orthopedic surgery

         10. Blood or blood product transfusion within 60 days prior to screening

         11. History of malignancy within 5 years prior to registration

         12. History of being positive for human immunodeficiency virus antibody, hepatitis B
             antigen and/or hepatitis C virus antibody

         13. Predisposition to infection, or history of recurrent infection or known
             immunodeficiency

         14. Use of any investigational product or investigational medical device within 4 months
             prior to screening, or requirement for any investigational agent prior to completion
             of all scheduled study assessments

         15. Receiving investigational agent in the UX023-CL301 study

         16. Use of a therapeutic monoclonal antibody other than KRN23 within 90 days prior to
             screening

         17. History of allergic or anaphylactic reactions to KRN23, any of the KRN23 ingredients,
             or any other monoclonal antibodies

         18. Anyone otherwise considered unsuitable participation in the study by the investigator
             or subinvestigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kanagawa Prefectural Hospital Organization Kanagawa Children's Medical Center</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagwa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Corporation Osaka University Hospital</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Hospital, Japan Community Healthcare Organization (JCHO)</name>
      <address>
        <city>Ōsaka</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama Saiseikai General Hospital Outpatient Center</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2017</study_first_submitted>
  <study_first_submitted_qc>July 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2017</study_first_posted>
  <last_update_submitted>October 9, 2017</last_update_submitted>
  <last_update_submitted_qc>October 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rickets</mesh_term>
    <mesh_term>Osteomalacia</mesh_term>
    <mesh_term>Rickets, Hypophosphatemic</mesh_term>
    <mesh_term>Familial Hypophosphatemic Rickets</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

